


Journal Pre-proof

First Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing

Anna R. Wolfson, MD, Lacey B. Robinson, MD, MPH, Lily Li, MD, Aubree E. McMahon, BA, Amelia S. Cogan, MPH, Xiaoqing Fu, MS, Paige Wickner, MD, MPH, Upeka Samarakoon, MS, PhD, Rebecca R. Saff, MD, PhD, Kimberly G. Blumenthal, MD, MSc, Aleena Banerji, MD



PII: S2213-2198(21)00675-9

DOI: <https://doi.org/10.1016/j.jaip.2021.06.010>

Reference: JAIP 3674

To appear in: *The Journal of Allergy and Clinical Immunology: In Practice*

Received Date: 17 April 2021

Revised Date: 28 May 2021

Accepted Date: 2 June 2021

Please cite this article as: Wolfson AR, Robinson LB, Li L, McMahon AE, Cogan AS, Fu X, Wickner P, Samarakoon U, Saff RR, Blumenthal KG, Banerji A, First Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing, *The Journal of Allergy and Clinical Immunology: In Practice* (2021), doi: <https://doi.org/10.1016/j.jaip.2021.06.010>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 American Academy of Allergy, Asthma & Immunology

1 First Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin

2 Testing

3
4 Anna R. Wolfson, MD^{1,2}

5 Lacey B. Robinson, MD, MPH^{1,2}

6 Lily Li, MD^{1,3}

7 Aubree E. McMahon, BA²

8 Amelia S. Cogan, MPH²

9 Xiaoqing Fu, MS²

10 Paige Wickner, MD, MPH^{1,3}

11 Upeka Samarakoon, MS, PhD²

12 Rebecca R. Saff, MD, PhD^{1,2}

13 *Kimberly G. Blumenthal, MD, MSc^{1,2,4}

14 *Aleena Banerji, MD^{1,2}

15
16 ¹ Harvard Medical School, Boston, MA

17 ² Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts
18 General Hospital, Boston, MA

19 ³ Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA

20 ⁴ Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital, Boston,
21 MA

22 *Co-senior authors

23

24 **Corresponding Author:** Anna R. Wolfson, MD, Massachusetts General Hospital, Allergy and
25 Immunology, Cox 201, 55 Fruit Street, Boston, MA 02114, p-(617) 726-3850, f- (617) 724-
26 0239, awolfson@mgh.harvard.edu; Twitter: @AnnaWolfsonMD

27

28 **E-mail addresses:**

29 Anna R. Wolfson awolfson@mgh.harvard.edu

30 Lacey B. Robinson lbrobinson@mgh.harvard.edu

31 Lily Li lli39@bwh.harvard.edu

32 Aubree E. McMahon aemcmahon@mgh.harvard.edu

33 Amelia S. Cogan ascogan@mgh.harvard.edu

34 Xiaoqing Fu xfu2@mgh.harvard.edu

35 Paige Wickner pwickner@bwh.harvard.edu

36 Upeka Samarakoon ssamarakoon@mgh.harvard.edu

37 Rebecca R. Saff rsaff@mgh.harvard.edu

38 Kimberly G. Blumenthal kblumenthal@mgh.harvard.edu

39 Aleena Banerji abanerji@mgh.harvard.edu

40

41 **Contents:**

42 Abstract Word count: 261

43 Text Word count: 4140

44 Tables: 6

45 Figures: 3

46 References: 31

47

48 **Funding:**

49 This work was supported by National Institutes of Health K01AI125631 and the Massachusetts
50 General Hospital Department of Medicine Transformative Scholar Award. The content is solely
51 the responsibility of the authors and does not necessarily represent the official views of the
52 National Institutes of Health or MGH.

53 **Conflict of Interest:**

54 ARW, LBR, LL, XF, PW, US, AEM, ASC, RRS, KGB, AB have nothing to disclose relevant to
55 this paper.

56

57

58

59 **Abstract:**

60 **Background:** CDC states that a severe or immediate allergic reaction to the first dose of an
61 mRNA COVID-19 vaccine is a contraindication for the second dose.

62 **Objective:** To assess outcomes associated with excipient skin testing after a reported allergic
63 reaction to mRNA COVID-19 vaccine dose one.

64 **Methods:** We identified a consecutive sample of patients with reported allergic reactions after
65 the first dose of mRNA COVID-19 vaccine who underwent allergy assessment with skin testing
66 to polyethylene glycol (PEG) and, if appropriate, polysorbate 80. Skin testing results in
67 conjunction with clinical phenotyping of the first dose mRNA COVID-19 vaccine reaction
68 guided second dose vaccination recommendation. Second dose mRNA COVID-19 vaccine
69 reactions were assessed.

70 **Results:** 80 patients with reported first dose mRNA COVID-19 vaccine allergic reactions (n=65,
71 81% immediate onset) underwent excipient skin testing. 14 (18%) had positive skin tests to PEG
72 (n=5) and/or polysorbate 80 (n=12). Skin testing result did not impact tolerance of second dose
73 in patients with immediate or delayed reactions. Of 70 (88%) patients who received their second
74 mRNA COVID-19 vaccine dose, 62 (89%) had either no reaction or a mild reaction managed
75 with antihistamines, but two patients required epinephrine. Three patients with positive PEG-
76 3350 intradermal (methylprednisolone) testing tolerated second dose mRNA COVID-19
77 vaccination. Refresh Tears caused non-specific irritation.

78 **Conclusion:** Most individuals with a reported allergic reaction to dose one of the mRNA
79 COVID-19 vaccines, regardless of skin test result, received the second dose safely. More data
80 are needed on the value of skin prick testing to PEG (Miralax) in evaluating patients with mRNA
81 COVID-19 vaccine anaphylaxis. Refresh Tears should not be used for skin testing.

82

83

84

85 **Highlights Box:**

86 1. What is already known about this topic? An expert-informed risk stratification protocol was
87 recommended to guide clinical care after mRNA COVID-19 vaccine reactions, however, at the
88 time there was no supportive evidence available.

89 2. What does this article add to our knowledge? Most individuals after first dose mRNA COVID-
90 19 vaccine reactions, regardless of excipient skin testing result, were able to safely receive the
91 second mRNA COVID-19 vaccine dose. Refresh Tears were irritating and should not be used for
92 skin testing to polysorbate 80.

93 3. How does this study impact current management guidelines? More data on the value of skin
94 prick testing to PEG (Miralax) in evaluating patients with mRNA COVID vaccine anaphylaxis is
95 needed and the positive predictive value remains unknown. Most patients may be able to proceed
96 to second vaccination without skin testing.

97

98 **Key words:** *COVID-19 vaccine, drug allergy, vaccine allergy, COVID-19, PEG allergy, skin*
99 *testing, Polysorbate allergy, excipient allergy, anaphylaxis.*

100

101 **Abbreviations:**

102 Coronavirus Disease-2019 (COVID-2019)

103 Emergency Use Authorization (EUA)

104 Food and Drug Administration (FDA)

105 Centers for Disease Control and Prevention (CDC)

106 Polyethylene glycol (PEG)

107 Mass General Brigham (MGB)

108 E-consult (electronic consult)

109 Massachusetts General Hospital (MGH)

110 Brigham and Women's Hospital (BWH)

111 REDCap (Research Electronic Data Capture)

112 Electronic Health Record (EHR)

113 Standard Deviation (SD)

114 Interquartile Range (IQR)

115 Negative Predictive Value (NPV)

116 Intradermal (ID)

117 **Introduction:**

118 One year after the World Health Organization declared COVID-19 (Coronavirus Disease-2019)
119 a pandemic, greater than 138 million people have been infected and every country in the world
120 has been impacted.¹ It was with excitement and hope that millions of Americans welcomed the
121 approval of two novel COVID-19 mRNA vaccines in December 2020. However, almost
122 immediately following Emergency Use Authorization (EUA)² by the Food and Drug
123 Administration (FDA) of the Pfizer-BioNTech COVID-19 mRNA vaccine, initial reports of
124 anaphylaxis and allergic reactions began. When the Moderna COVID-19 mRNA vaccine was
125 approved soon thereafter, similar reports emerged.³ The reports of anaphylaxis prompted the
126 Centers for Disease Control and Prevention (CDC) to develop formal guidance for
127 administration of the Pfizer-BioNTech and the Moderna mRNA COVID-19 vaccines, stating that
128 patients with a history of anaphylaxis to vaccine components should not receive mRNA COVID-
129 19 vaccines,⁴ and patients with a history of an immediate allergic reaction to the first dose of
130 mRNA COVID-19 vaccine should not receive the second dose.⁵

131 In December, 2020, national anaphylaxis rates were reported by the CDC initially to be as high
132 as 11.1 per million doses of the Pfizer-BioNTech COVID-19 vaccine,⁶ but, by January, 2021,
133 CDC estimates reported an anaphylaxis incidence of 2.5 to 4.7 per million doses of the Moderna
134 and Pfizer-BioNTech COVID-19 vaccines, respectively.⁷ In the first prospective real world
135 cohort of 60,000 employees vaccinated at a large healthcare system (Mass General Brigham,
136 [MGB]), an incidence of 2.5 cases of anaphylaxis per 10,000 mRNA COVID-19 vaccines
137 administered was reported.⁸ The cause of allergic reactions to mRNA COVID-19 vaccines

138 remains unknown, but the excipient PEG-2000, present in the mRNA COVID-19 vaccines,⁹ has
139 been an important focus of investigation with recent limited supportive evidence.¹⁰ Furthermore,
140 the utility of skin testing to PEG and polysorbate 80 was unclear but experts suspected excipient
141 skin testing to have a high positive predictive value and a low negative predictive value.^{11,12} At
142 the time of publication, there are three COVID-19 vaccines which have received FDA EUA: two
143 contain PEG-2000 (Pfizer-BioNTech and Moderna mRNA COVID-19 vaccines) and one
144 contains polysorbate 80 (Janssen adenovirus vector vaccine). Thus, it is important to understand
145 whether there is a relationship between allergy to these excipients and allergic reactions to the
146 COVID-19 vaccines.⁹

147 Our risk stratification algorithm¹³ uses clinical history with skin testing to PEG and/or
148 polysorbate to evaluate higher risk individuals who report a history of an immediate allergic
149 reaction to a first dose of mRNA COVID-19 vaccine. Herein, we report the outcomes of
150 individuals referred for reported allergic reactions to a first dose of mRNA COVID-19 vaccine
151 that completed skin testing and followed our initial published skin testing guidance.¹³ We review
152 patient and reaction characteristics with skin testing findings along with second dose vaccine
153 outcomes that motivate an updated approach to individuals who present following a reported
154 allergic reaction to the first dose of mRNA COVID-19 vaccine.

155

156 **Methods:**

157 This cohort included consecutive patients referred for an in-person allergy/immunology excipient
158 skin testing visit which occurred at MGB between January 6 and March 3, 2021 after a first dose
159 mRNA COVID-19 vaccine reaction. In-person visits occurred after initial allergy/immunology
160 telemedicine visits with clinical phenotyping and risk stratification. All included patients
161 received their first mRNA vaccine dose at an MGB vaccination clinic with second doses
162 scheduled at the vaccination clinics associated with the MGB academic medical centers:
163 Massachusetts General Hospital (MGH) or Brigham and Women's Hospital (BWH).

164 We recommended excipient skin testing to all patients who reported symptoms concerning for an
165 IgE-mediated allergy within 4 hours of vaccination. Patients with symptoms consistent with an
166 allergic reaction which was delayed (occurring more than 4 hours after vaccination but before
167 day 3 post vaccination) may also have proceeded to excipient skin testing, especially if the
168 symptoms were more severe or patient preference using shared decision-making. For patients
169 who reported symptoms which were potentially IgE-mediated but subjective (e.g., globus or itch
170 without rash), the decision to proceed to skin testing was also based on shared decision-making
171 considering patient preferences. Interested and eligible patients were referred for an in-person
172 excipient skin testing appointment at either MGH or BWH. Approximately 14% of patients with
173 first dose mRNA COVID-19 vaccine reactions were referred for in-person excipient skin testing
174 using our algorithm.¹³

175

176 At MGH, PEG skin testing was performed using Miralax, a laxative containing PEG-3350,
177 epicutaneous and methylprednisolone acetate (containing PEG-3350 only¹³) intradermally
178 (Table E1).¹³ If methylprednisolone acetate was positive, methylprednisolone sodium succinate

179 was used as a control to exclude methylprednisolone as the cause of allergy. At MGH, for
180 individuals with first dose mRNA COVID-19 vaccine reactions, skin testing to polysorbate 80
181 (using triamcinolone acetonide¹⁴) was performed if PEG skin testing was positive to help guide
182 future COVID-19 vaccination or if the patient reported a history of a reaction to another vaccine
183 containing polysorbate 80. At BWH, PEG (Miralax and methylprednisolone acetate containing
184 PEG 3350 only) skin testing was similar although polysorbate 80 testing used Refresh Tears and
185 was performed regardless of PEG skin testing result. All sites required adequate positive
186 (histamine) and negative (saline) controls for epicutaneous and intradermal tests. Patients with
187 negative skin testing were advised to proceed to second dose mRNA COVID-19 vaccination.
188 Shared decision-making was used for patients with positive skin test to PEG and/or polysorbate
189 80.

190
191 We used excipient skin testing alone -- without mRNA COVID-19 vaccine skin testing --which
192 has since been described,^{15,16} as we did not have access at the time to mRNA COVID-19 vaccine
193 for skin testing purposes and the mRNA COVID-19 vaccines were the first vaccines of their
194 kind. It was not apparent that any prior vaccine guidance¹⁷ could be accurately applied to these
195 vaccines and there was initial concern that dilution could degrade mRNA so it could not be used
196 as a skin testing product nor as a graded challenge.¹⁸

197
198 Due to concern which arose during this study for irritant skin testing reactions to Refresh Tears,
199 control skin tests were performed on 25 non-allergic subjects who reported clinical tolerance to
200 polysorbate 80.

201 *Data Collection and Definitions*

202 Clinical data were gathered from manual electronic health record (EHR) review by trained
203 research assistants (AEM, ASC) with allergist oversight (ARW, LBR, LL). Structured MGB
204 allergist note templates used during clinic visits facilitated accurate demographic, past medical
205 and allergy history, skin test results, and outcomes. Study data were collected and managed using
206 REDCap (Research Electronic Data Capture) tools.^{19,20}

207
208 Immediate allergic reactions were defined as occurring within the first four hours, and delayed
209 allergic reactions occurred anytime thereafter. Reaction details were categorized by organ system
210 of involvement. Cutaneous included itching, rash, hives, flushing and swelling. Cardiovascular
211 included hypotension and tachycardia. Lower respiratory included cough, wheezing, chest
212 tightness or shortness of breath. Upper airway included globus, hoarseness, and throat swelling.
213 Gastrointestinal included abdominal pain, nausea, vomiting, and diarrhea.

214
215 For patients who received their second mRNA COVID-19 vaccination, we assessed tolerance of
216 the vaccine using three days of electronically-disseminated symptoms surveys. If a patient did
217 not respond to all three days of the survey, or if they reported allergic symptoms on the survey,
218 they were contacted by phone or e-mail message by an allergist/immunologist (ARW) to assess
219 tolerance of the second dose of mRNA COVID-19 vaccine. Individuals who received the
220 Janssen vaccine in lieu of second mRNA COVID-19 vaccines were considered to have not
221 received their second mRNA COVID-19 vaccine dose but to have been completely vaccinated.

222
223 The index allergic reaction to the first mRNA COVID-19 vaccine and, when relevant, the
224 allergic reaction to the second mRNA COVID-19 vaccine, were graded using Ring and Messmer

225 criteria²¹ (Table E2) by two allergists independently; in the case of discordant grading, a third
226 allergist was used to determine the final grade (ARW, LBR, LL). We defined second dose
227 tolerance as either no allergic reaction or a grade 0 reaction with mild subjective symptoms that
228 did not require treatment.

229

230 This study was approved by the MGB Partners Institutional Review Board, protocol number
231 2020P004068.

232

233 *Data Analysis*

234 Data are presented as counts with frequencies for categorical data and means with standard
235 deviation (SD) or medians with interquartile ranges (IQR) for continuous variables, as indicated.

236 All analyses were performed in SAS (version 9.4, Cary, NC, USA). We calculated the negative
237 predictive value (NPV) for PEG skin testing result and having a reaction with mRNA COVID-19
238 vaccine dose two for the entire sample and considering only patients with immediate reactions.

239

240 **Results:**

241 There were 80 patients who underwent excipient skin testing at MGB after a reported allergic
242 reaction to the first dose of mRNA COVID-19 vaccine (**Table 1**). 18 (23%) reported a reaction
243 to Pfizer-BioNTech and 62 (77%) to the Moderna COVID-19 mRNA vaccine. 38,933 (60%)
244 Moderna and 25,906 (40%) Pfizer-BioNTech vaccines were administered at MGB during the
245 study period and a total of 576 allergy/immunology telehealth visits were performed for
246 COVID-19 vaccine reactions.

247

248 *Patient Characteristics*

249 Patients were predominantly female (89%) and white (78%) with mean age 40.9 ± 13.6 years.

250 Past medical history included a history of non-anaphylactic IgE mediated food allergy (n=29,

251 36%), asthma (n=25, 31%), anaphylaxis to medications, foods, venom or latex (n=22, 28%),

252 allergic rhinitis (n=20, 25%), polysorbate allergy (n=5, 6%), atopic dermatitis (n=4, 5%), and

253 PEG allergy (n=2, 3%) (**Table 1**).

254

255 *Reaction Characteristics*

256 There were 65 (81%) patients reporting an immediate reaction; 40 (62%) occurred within the

257 first 30 minutes with the median onset of symptoms within 10 [IQR: 5,15] minutes. The

258 following symptoms were reported: cutaneous (n=51, 78%), lower respiratory (n=14, 22%),

259 cardiovascular (n=10, 15%), and subjective symptoms including lightheadedness and tingling

260 (n=21, 32%). 47 (72%) patients received antihistamine treatment and 6 (9%) received

261 epinephrine; 18 (28%) were treated in the emergency department. Of the 65 immediate allergic

262 reactions, 21 (32%) were grade 0, 33 (51%) were grade 1, and 11 (17%) were grade 2. All

263 individuals recovered from their reaction without long-term sequelae.

264

265 There were 15 (19%) patients who experienced delayed allergic reactions; 1 (7%) patient

266 received Pfizer and 14 (93%) received Moderna (**Table 1**). Of these, 11 (73%) had symptoms

267 within the first 24 hours after receiving the vaccine and 4 (27%) had symptoms starting 24 hours

268 or more after the vaccine was administered. The delayed symptoms were most frequently

269 cutaneous (n=14, 93%), other symptoms as in Table 1. One patient was treated in the emergency

270 department.

271
272 *Skin Testing Results*
273 Of the 80 patients who underwent excipient skin testing, 33 had testing to PEG only, 47 had
274 testing to PEG and polysorbate 80 (n=41 to Refresh Tears; n=6 to triamcinolone acetonide). In
275 all, 14 (18%) had a positive skin test result (**Table 2**): PEG only (n=2), PEG and polysorbate 80
276 (n=3), and polysorbate 80 only (n=9, **Figure 1a**). All polysorbate 80 positive individuals were
277 positive on skin testing to Refresh Tears (n=12), which was found to be an irritant in 13 of 25
278 (52%) non-allergic controls (**Table E3**). Among the 65 patients presenting with an immediate
279 allergic reaction, 8 (12%) had positive skin tests: PEG (n= 2), PEG and polysorbate 80 (n=2),
280 and polysorbate 80 (n=4, **Figure 1b**). These patients with PEG positive skin tests were positive
281 on intradermal testing to methylprednisolone acetate 4 mg/mL (n=1), methylprednisolone acetate
282 0.4 mg/mL (n=2) and to Miralax 1:100 epicutaneous (n=1). Among the 15 patients with a
283 delayed allergic reaction, 6 (40%) had positive skin testing: 5 (33%) to polysorbate 80 and 1
284 (7%) to both PEG (intradermal testing to methylprednisolone acetate 0.4mg/mL) and polysorbate
285 80 (**Figure 1c**). No allergic or adverse events occurred during any skin testing procedures.

286

287 *Tolerance of the Second Dose of the Vaccine Overall*

288 Of the 80 patients who underwent excipient skin testing, 70 (88%) received a second dose of the
289 same mRNA COVID-19 vaccine and 52 (74%) tolerated the second dose vaccine without a
290 reaction (**Figure 1a**). The NPV of a negative skin test to PEG predicted a 75% likelihood of
291 tolerating the second dose of the vaccine

292

293 Among the 65 patients who reported an immediate allergic reaction to the first dose of mRNA
294 COVID-19 vaccine, 58 (89%) received their second dose of the vaccine, and 43 (74%) tolerated
295 their second dose without reaction (**Figure 1b**); 2 (3%) received epinephrine treatment for their
296 second dose reaction. Among the 65 patients who reported an immediate reaction to the first
297 dose of mRNA COVID-19 vaccine, the NPV of a negative skin test to PEG was 75%.

298

299 *Tolerance of the Second Dose of the Vaccine Among Skin Test Negative Patients*

300 Overall, 66 (83%) patients were skin test negative and 60 (91%) of these patients went on to
301 receive their second dose of the vaccine, 45 (75%), ultimately had the second dose of the vaccine
302 without recurrent symptoms. Among the 65 patients who reported an immediate allergic reaction
303 to the first dose of mRNA COVID vaccine, 57 (88%) were skin test negative, 52 (80%) received
304 their second dose of the vaccine, and 39 (75%) had no symptoms with the second dose. There
305 were 13 (25%) patients who were skin test negative but reacted to the second dose of the
306 vaccine, and their most common symptoms were cutaneous (n=11) but 4 (31%) patients were
307 seen in the Emergency Department and 2 (15%) received epinephrine (**Table 3**).

308 Among the 15 individuals who reported a delayed reaction after the first dose of mRNA
309 COVID-19 vaccine, 9 (60%) were skin test negative and 8 (89%) received their second vaccine
310 dose; 6 of 8 (75%) tolerated the second dose without reaction. Two patients who were skin test
311 negative but reacted to the second dose of the vaccine reported the following symptoms: one had
312 mild swelling of throat, tongue, and eyes, pruritus without rash on face and chest, no treatment
313 was sought; one had pruritus and erythema of arms, with pruritus of lips and neck, treated with
314 antihistamines.

315

316 *Tolerance of the Second Dose of the Vaccine Among Skin Test Positive Patients*

317 Among the 8 (12%) patients who reported a history of an immediate allergic reaction and a
318 positive skin test: 4 (67%) tolerated the vaccine (skin test positive to: polysorbate 80/Refresh
319 Tears [n=2], PEG/methylprednisolone acetate ID [n=1], PEG/ methylprednisolone acetate ID
320 and polysorbate 80/Refresh Tears [n=1]); 2 (33%) had mild allergic reactions; 2 (25%) after
321 shared decision-making, opted to not receive the second mRNA COVID-19 vaccine dose (both
322 skin test positive to PEG, 1 patient was skin prick positive to Miralax and 1 patient opted to
323 instead receive the Janssen vaccine) (**Table 2**). The two patients with dose two reactions were
324 positive to Refresh Tears and both had mild symptoms. The two patients who had PEG skin test
325 positive but tolerated the vaccine were positive to methylprednisolone acetate on intradermal
326 testing; the only patient with a positive to Miralax on epicutaneous testing had experienced
327 anaphylaxis requiring epinephrine after the first dose of the vaccine and was not re-challenged.

328
329 Among the 15 patients who reported a delayed allergic reaction to the first dose of mRNA
330 COVID-19 vaccine, there were 6 with a positive skin test, 3 tolerated the vaccine (skin test
331 positive to: polysorbate 80/Refresh Tears [n=2], PEG/methylprednisolone acetate ID and
332 polysorbate 80/Refresh Tears [n=1]); 1 had a mild allergic reaction; and 2 have not received dose
333 two (skin test positive to polysorbate 80/Refresh Tears). The patient who had a dose two
334 reaction was positive to polysorbate 80/Refresh Tears and experienced subjective symptoms
335 (**Table 2**). The patient with positive skin testing to PEG was positive only on intradermal testing
336 to methylprednisolone acetate.

337
338 **Discussion:**

339 Among 80 individuals referred for excipient skin testing after a reported allergic reaction to the
340 first dose of mRNA COVID-19 vaccine the vast majority of patients received the second mRNA
341 COVID-19 vaccine dose safely irrespective of skin test results. Two patients who were treated
342 with epinephrine after their second dose had been treated with epinephrine after their first dose
343 as well. However, three additional patients that received epinephrine after their first dose
344 tolerated their second vaccine, therefore, while there are no clear risk factors, this is an important
345 issue for physicians to discuss with patients that were treated with epinephrine after the first dose
346 of the mRNA COVID-19 vaccine. Notably, it is possible that epinephrine was not necessary in
347 these cases. Overall, excipient skin testing did not add value to the clinical risk assessment in
348 those reporting first dose mRNA COVID-19 vaccine reactions even when applied to a highly
349 selected group that represented just 14% of mRNA COVID-19 vaccine reactions evaluated by
350 allergy/immunology in this period overall. However, PEG skin prick testing may be useful in
351 guiding second dose vaccination in individuals with anaphylaxis to the first dose of the mRNA
352 COVID-19 vaccine although its positive predictive value remains unknown.

353
354 Based on our data and experience to date, we propose an updated risk stratification algorithm
355 after reported first dose mRNA COVID-19 vaccine allergic reactions (**Figure 2**). First, the
356 clinical history still remains the most important aspect in the allergist evaluation; using shared
357 decision-making, most individuals with reactions to the first dose of an mRNA COVID-19
358 vaccine can proceed safely with second dose.²²⁻²⁴ Second, excipient skin testing is favored over
359 vaccine skin testing,^{15,16} as vaccine is largely inaccessible to most allergists and the mRNA
360 vaccines are still under EUA. Third, in terms of premedication, although some patients in the
361 cohort were pre-treated with antihistamines or steroids, this study was not designed to determine

362 an optimal premedication regimen. The authors have used premedication with non-sedating
363 antihistamines for patients with mild symptoms such as delayed urticaria, but try to restrict use of
364 glucocorticoids that may have an unfavorable immunologic effect.²⁵ Fourth, in our experience to date,
365 PEG skin testing was of limited utility (n=5 with positive skin tests), and should only be
366 considered in specific cases, e.g. patients with convincing history of anaphylaxis to mRNA
367 COVID-19 vaccine or recently to oral PEG-containing medications. Lastly, methylprednisolone
368 acetate or PEG intradermal skin testing did not provide additional information to guide safety of
369 second dose mRNA COVID-19 vaccination as patients (n=3) with positive skin testing to this
370 tolerated the vaccine, in our experience. We thus suggest that, when PEG excipient testing is
371 warranted, epicutaneous testing to Miralax (PEG3350) alone is adequate.^{10,11,12} In our
372 experience, consistent with rare true cases of anaphylaxis to the COVID-19 mRNA vaccines,
373 Miralax skin testing was positive in one patient with symptoms consistent with anaphylaxis. This
374 patient did not receive a second dose of COVID-19 vaccine so the positive predictive value of
375 Miralax skin testing remains unknown.^{10,26} **(Figure E1).**

376 The cause of mRNA COVID-19 vaccine allergic reactions remains unclear and may be
377 multifactorial, but one case report linked PEG as a possible allergen¹⁰ and an improved
378 understanding of the role for excipient skin testing to PEG in individuals with a history of
379 anaphylaxis to mRNA COVID-19 vaccines is still needed. While we were able to calculate the
380 NPV for PEG skin testing and tolerance with dose two, we were unable to calculate sensitivity,
381 specificity, and/or positive predictive value. There were two patients who reported histories of
382 being allergic to PEG (reported after their first dose mRNA COVID-19 vaccine reaction).
383 Interestingly, both were PEG skin test negative and 1 patient tolerated dose two without
384 symptoms and the other developed subjective globus sensation after dose two treated with

385 antihistamines only. Three patients positive on intradermal PEG (methylprednisolone acetate)
386 skin testing tolerated their second mRNA COVID-19 vaccine dose without any reactions.
387 Additionally, in our experience, a portion of skin test negative patients had reactions to their
388 mRNA COVID-19 vaccine second dose. While the majority had easily treatable reactions and
389 are now fully vaccinated, importantly, two were treated with epinephrine and four were treated in
390 the Emergency Department, emphasizing the important role for an allergist in the care of these
391 patients. Thus, since skin test positive patients tolerated the second dose of the vaccine and skin
392 test negative patients had reactions, skin testing did not add additional information regarding the
393 tolerance of the second mRNA COVID-19 vaccine dose.

394 Due to the high rate of skin test positivity to Refresh Tears, which was used as a source of
395 polysorbate 80 in the BWH study population, we tested a new control group (Table E3).
396 Approximately half of the non-allergic controls had positive skin test results suggesting that
397 Refresh Tears is likely causing an irritant, or false positive, skin test reaction. These findings
398 prompted us to modify our initial algorithmic approach and also to contact all MGB patients with
399 positive skin tests to Refresh Tears to modify our initial advice and encourage mRNA COVID-
400 19 vaccination. None of the patients with positive skin tests to Refresh Tears that received the
401 second dose of the mRNA COVID-19 vaccine developed an allergic reaction, but three patients
402 had subjective symptoms and were treated with antihistamines only.

403 Vaccine hesitancy is an important issue that may be exacerbated by adverse and/or allergic
404 symptoms after the first dose of the mRNA COVID-19 vaccine, and we are eager to reassure our
405 patients regarding the vaccine's safety in order to encourage vaccination.²⁷ In our cohort of
406 individuals referred for skin testing, 10 out of 80 have not received their second dose of mRNA

407 COVID-19 vaccine, although only 2 were advised by our group to not receive mRNA COVID-
408 19 vaccine (a third patient received Janssen vaccine). The reasons for incomplete vaccination are
409 not clear, but may include vaccine administration logistics, unclear benefit of second dose
410 vaccination, and/or concern about having a recurrent allergic or adverse reaction.²⁸ The allergist
411 may not be able to address all these barriers, but the allergist can acknowledge them,²⁹ and,
412 based on these data, provide reassurance around receiving the second dose if the clinical history
413 is low risk.^{12,13,16,30} The allergist also has an important role in helping to correctly recognize and
414 treat allergic reactions, so allergist-observed second dose vaccinations may help reassure our
415 patients.

416 Recently, the CDC added guidance allowing Janssen COVID-19 vaccine at least 28 days after an
417 allergic reaction to a first dose of mRNA COVID vaccine, broadening our patients' options.⁵ The
418 Janssen COVID-19 vaccine contains the excipient polysorbate 80 but not PEG and therefore
419 could be administered without skin testing to PEG in patients concerned about PEG allergy.
420 Janssen COVID-19 vaccine could also be considered in an individual with a history of PEG
421 allergy or PEG skin test positivity but a negative polysorbate 80 skin test or tolerance of vaccine
422 with polysorbate 80 (**Figure 2**). Reassuringly, to date, the rate of allergic reactions to the
423 Janssen vaccine appears exceedingly low.³¹ One patient in our cohort who had reported an
424 immediate allergic reaction to Moderna, then had positive skin testing to methylprednisolone
425 acetate and Refresh Tears has subsequently tolerated the Janssen vaccine. This is an important
426 option for our high-risk patients with possible PEG allergy.

427 The limitations of our study include generalizability as our study population was a referred
428 population consisting of MGB patients evaluated by a specialist. The majority of our patients

429 were white females, which was likely a reflection of the overrepresentation of white females in
430 the healthcare worker population in the Boston area. The demographics may limit
431 generalizability across demographics although these demographics closely match those reported
432 nationally.^{3,6,7} These data are subject to information bias as we do not know why some
433 individuals chose not to receive their second dose of the vaccine, even when the allergist advised
434 that it was safe to proceed. Given that proceeding to a second mRNA COVID-19 vaccine dose
435 was not at random, we acknowledge that there is a bias in calculation of an NPV. However,
436 while NPV could be calculated given that only 9% of skin test negative patients did not receive
437 dose two, we were unable to calculate PPV given that 40% of skin test positive patients did not
438 receive dose two and sample size was just 5. Another limitation is that symptoms were self-
439 reported. Although we intended to only use excipient skin testing in high risk individuals, some
440 individuals reported minor and subjective symptoms (e.g. itch, globus, dizziness); including these
441 symptoms in our analysis may have made it more difficult to ascertain the association of
442 excipient skin testing with true mRNA COVID-19 vaccine allergy. However, the inclusion of
443 these patients was due to patient preference and shared decision-making.

444 Overall, our initially published risk stratification protocol¹³ allowed safe second dose mRNA
445 COVID-19 vaccination for the vast majority of individuals despite a reported first dose allergic
446 reaction. We have since learned that excipient skin testing may be of little utility in the
447 assessment of these reactions, particularly in individuals without anaphylaxis. More data are
448 needed to identify whether PEG skin prick testing after a reaction clinically consistent with
449 severe anaphylaxis to mRNA COVID vaccine is predictive of a reaction with subsequent mRNA
450 COVID-19 vaccine. Additional studies focusing on specific reaction phenotypes, notably
451 anaphylaxis, may enable us to better risk stratify and optimize our recommendations for

452 subsequent COVID-19 vaccination after immediate allergic reactions. As experiences
453 accumulate, similar to the revised algorithm included in this study, we will update our clinical
454 approach to provide up-to-date guidance for individuals with a presumed reaction to the first
455 dose of the mRNA COVID-19 vaccine.

456

457

Journal Pre-proof

458 **References:**

- 459
460
- 461 1. Coronavirus Resource Center. COVID-19 Dashboard by the Center for Systems Science
462 and Engineering (CSSE) at Johns Hopkins University & Medicine. Baltimore, MD: Johns
463 Hopkins University & Medicine; 2021. Available at:
464 <https://coronavirus.jhu.edu/map.html> Accessed March 17, 2021.
 - 465 2. US Food and Drug Administration EUA for Pfizer-BioNTech Vaccine. Available at:
466 [https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine)
467 [covid-19/pfizer-biontech-covid-19-vaccine](https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine). Accessed March 7, 2021.
 - 468 3. Gee, J, Marquez, P, Su, J, Calvert, G. M, Liu, R, Myers, T, et al. First Month of COVID-
469 19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021.
470 *MMWR Morb Mortal Wkly Rep.* 2021;70(8):283-288.
 - 471 4. Information about COVID-19 Vaccines for People with Allergies. Atlanta, GA: Center
472 for Disease Control and Prevention; 2021. Available at:
473 [https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/specific-](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/specific-groups/allergies.html)
474 [groups/allergies.html](https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/specific-groups/allergies.html). Accessed April 13, 2021.
 - 475 5. What to Do if You Have an Allergic Reaction After Getting A COVID-19 Vaccine.
476 Atlanta, GA: Center for Disease Control and Prevention; 2021. Available at:
477 <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/allergic-reaction.html>
478 Accessed April 13, 2021.
 - 479 6. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-
480 BioNTech COVID-19 Vaccine - United States, December 14-23, 2020. *MMWR Morb*
481 *Mortal Wkly Rep.* 2021;70(2):46-51.
 - 482 7. Shimabukuro TT, Cole M, Su JR. Reports of Anaphylaxis After Receipt of mRNA
483 COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. *Jama.* 2021.
 - 484 8. Blumenthal KG, Robinson LB, Camargo CA Jr, Shenoy ES, Banerji A, Landman AB,
485 Wickner P. Acute Allergic Reactions to mRNA COVID-19 Vaccines. *Jama.* 2021.
 - 486 9. Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. *N Engl J Med.*
487 2021;384(7):643-649.
 - 488 10. Sellaturay P, Nasser SM, Islam S, Gurugama P, Ewan PW. Polyethylene glycol (PEG) is
489 a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine. *Clin Exp*
490 *Allergy.* 2021.
 - 491 11. Stone CA, Jr., Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, et al. Immediate
492 Hypersensitivity to Polyethylene Glycols and Polysorbates: More Common Than We
493 Have Recognized. *The journal of allergy and clinical immunology In practice.*
494 2019;7(5):1533-1540 e1538.
 - 495 12. Pitlick MM, Sitek AN, Kinate SA, Joshi AY, Park MA. Polyethylene glycol and
496 polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions:
497 Early report. *Ann Allergy Asthma Immunol.* 2021.
 - 498 13. Banerji A, Wickner PG, Saff R, Stone CA Jr, Robinson LB, Long AA, Wolfson AR,
499 Williams P, Khan DA, Phillips E, Blumenthal KG. mRNA Vaccines to Prevent COVID-
500 19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.
501 *J Allergy Clin Immunol Pract.* 2020.

- 502 14. Broyles AD, Banerji A, Barmettler S, Biggs CM, Blumenthal K, Brennan PJ, et al.
503 Practical Guidance for the Evaluation and Management of Drug Hypersensitivity:
504 Specific Drugs. *J Allergy Clin Immunol Pract.* 2020;8(9s):S16-s116.
- 505 15. Marcelino J, Farinha S, Silva R, Didenko I, Proença M, Tomás E. Non-irritant
506 concentrations for skin testing with SARS-CoV-2 mRNA Vaccine. *J Allergy Clin*
507 *Immunol Pract.* 2021.
- 508 16. Bianchi L, Biondi F, Hansel K, Murgia N, Tramontana M, Stingeni L. Skin tests in
509 urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: limits of
510 intradermal testing. *Allergy.* 2021.
- 511 17. Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI, Blessing-Moore J, et al.
512 Adverse reactions to vaccines practice parameter 2012 update. *J Allergy Clin Immunol.*
513 2012;130(1):25-43.
- 514 18. Mustafa SS, Ramsey A, Staicu ML. Administration of a Second Dose of the Moderna
515 COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose:
516 Two Case Reports. *Ann Intern Med.* 2021.
- 517 19. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap
518 consortium: Building an international community of software platform partners. *Journal*
519 *of Biomedical Informatics.* 2019;95:103208.
- 520 20. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic
521 data capture (REDCap)—A metadata-driven methodology and workflow process for
522 providing translational research informatics support. *Journal of Biomedical Informatics.*
523 2009;42(2):377-381.
- 524 21. Ring J, Messmer K. Incidence and severity of anaphylactoid reactions to colloid volume
525 substitutes. *Lancet.* 1977;1(8009):466-469.
- 526 22. Iammatteo M, Ferastraoaru D, Koransky R, Alvarez-Arango S, Thota N, Akenroye A,
527 Jerschow E. Identifying Allergic Drug Reactions Through Placebo-Controlled Graded
528 Challenges. *J Allergy Clin Immunol Pract.* 2017;5(3):711-717.e712.
- 529 23. Sampath V, Rabinowitz G, Shah M, Jain S, Diamant Z, Jesenak M, et al. Vaccines and
530 Allergic reactions: the past, the current COVID-19 pandemic, and future perspectives.
531 *Allergy.* 2021.
- 532 24. Kelso JM. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines.
533 *Ann Allergy Asthma Immunol.* 2021.
- 534 25. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, et al.
535 Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of
536 mRNA Vaccines to SARS-CoV-2. *medRxiv.* 2021.
- 537 26. Turk VE. Anaphylaxis associated with the mRNA COVID-19 vaccines: Approach to
538 allergy investigation. *Clin Immunol.* 2021;227:108748.
- 539 27. Greenhawt M, Abrams EM, Oppenheimer J, Vander Leek TK, Mack DP, Singer AG,
540 Shaker M. The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis
541 Risk While Safely Vaccinating the World. *J Allergy Clin Immunol Pract.*
542 2021;9(4):1438-1441.
- 543 28. Hause AM, Gee J, Johnson T, Jazwa A, Marquez P, Miller E, et al. Anxiety-Related
544 Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass
545 Vaccination Sites, April 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(18):685-688.

- 546 29. Blumenthal KG, Li Y, Acker WW, Chang Y, Banerji A, Ghaznavi S, et al. Multiple drug
 547 intolerance syndrome and multiple drug allergy syndrome: Epidemiology and
 548 associations with anxiety and depression. *Allergy*. 2018;73(10):2012-2023.
- 549 30. Shaker M, Phillips E, Blumenthal KG, Abrams EM, Banerji A, Oppenheimer J, et al. The
 550 Importance of a Timely Second Dose of the 2021 COVID-19 mRNA Vaccine Depends
 551 on the Protection Afforded by a First Dose and Subsequent Risk of Anaphylaxis. *J*
 552 *Allergy Clin Immunol Pract*. 2021.
- 553 31. Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers)
 554 Emergency Use Authorization (EUA) of the Janssen COVID-19 Vaccine to prevent
 555 Coronavirus Disease 2019 (COVID-19) Available at:
 556 [https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-](https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-Recipient-fact-sheet.pdf)
 557 [19+Vaccine-Recipient-fact-sheet.pdf](https://www.janssenlabels.com/emergency-use-authorization/Janssen+COVID-19+Vaccine-Recipient-fact-sheet.pdf). Accessed April 13, 2021.

560 **Figure 1:** Patients who were skin tested due to symptoms after mRNA COVID-19 vaccination
 561 that were concerning for an allergic reaction. **A:** All patients. **B:** Patients with immediate allergic
 562 reactions. **C:** Patients with delayed allergic reactions

563 *3 patients who had positive skin testing to both PEG and polysorbate are represented in the PEG
 564 category only in this figure.

565 †1 patient did not receive the next dose in the series and instead received Janssen.

566 ‡2 patients had a grade 0 reactions. 1 patient had a grade 1 reaction.

567 §3 patients had a grade 0 reaction. 9 patients had a grade 1 reaction, and 3 patients had a grade 2
 568 reaction.

569 ¶2 patients who had positive skin testing to both PEG and polysorbate are represented in the PEG
 570 category only for the purpose of this figure.

571 ¶¶1 patient did not receive the next dose in the series and instead received Janssen.

572 #1 patient had a grade 0 reaction. 1 patient had a grade 1 reaction.

573 **2 patients had a grade 0 reaction. 8 patients had a grade 1 reaction. 3 patients had a grade 2
 574 reaction.

575 ††1 patient who had positive skin testing to both PEG and polysorbate is represented in the PEG
 576 category only for the purpose of this figure.

577 ‡‡1 patient had a grade 0 reaction.


578 §§1 patient had a grade 0 reaction. 1 patient had a grade 1 reaction.


580 **Figure 2:** Management of patients who present with symptoms concerning for an allergic
 581 reaction to the first dose of mRNA COVID-19 vaccine. Use of Janssen vaccine (if available)
 582 may be appropriate following allergic reaction to the first dose of mRNA COVID-19 vaccine if
 583 allergy evaluation is not feasible or due to shared decision-making between patient and
 584 physician.


585
 586

PEG3350 (Miralax)	
Step 1 Epicutaneous	1:100 (1.7mg/mL)
Step 2 Epicutaneous	1:10 (17 mg/mL)
Step 3 Epicutaneous	1:1 (170 mg/mL)

	PEG3350	Polysorbate 80 (Choose One)	
	Miralax	Triamcinolone Acetonide (also contains carboxymethyl- cellulose)	Prevnar 13
Step 1 Epicutaneous	1:100 (1.7mg/mL)	40 mg/ml	1:10
Step 2 Epicutaneous	1:10 (17 mg/mL)		
Step 3 Epicutaneous	1:1 (170 mg/mL)		
Step 4 Intradermal		0.4 mg/ml	1:100
Step 5 Intradermal		.4 mg/ml	
Step 5 Intradermal		40 mg/ml	










Table 1. Characteristics of patients that completed skin testing. All patients were referred for skin testing due to symptoms suggestive of an IgE reaction after the first dose of mRNA COVID-19 vaccine.

Characteristic	All (n=80)	Immediate Allergic Reaction* (n=65)	Delayed Allergic Reaction† (n=15)
Demographics			
Age (mean, SD)	40.9 (±13.6)	42.4 (±12.4)	34.5 (±16.6)
Female Sex (n, %)	71 (89)	57 (88)	14 (93)
Race (n, %)			
White	62 (78)	51 (79)	11 (73)
Asian	7 (9)	5 (8)	2 (13)
Black or African American	4 (5)	3 (5)	1 (7)
Other	7 (9)	6 (9)	1 (7)
History of Atopy (n, %)			
Food Allergy	29 (36)	24 (37)	5 (33)
Asthma	25 (31)	19 (29)	6 (40)
History of Anaphylaxis	22 (28)	17 (26) [‡]	5 (33) [§]
Allergic Rhinitis	20 (25)	15 (23)	5 (33)
History of Polysorbate Allergy	5 (6)	3 (5)	2 (13)
Atopic Dermatitis	4 (5)	3 (4.6)	1 (6.7)
History of PEG Allergy	2 (3)	2 (3)	0 (0)
Reaction History (n, %)			
Cutaneous Symptoms [‡]	65 (81)	51 (78)	14 (93)
Lower Respiratory Symptoms [‡]	18 (23)	14 (22)	4 (27)
Cardiovascular Symptoms [#]	11 (14)	10 (15)	1 (7)
Gastrointestinal Symptoms ^{**}	9 (11)	7 (11)	2 (13)
Upper Airway Symptoms ^{††}	6 (8)	6 (9)	0 (0)
Other Symptoms	51 (64)	21 (32) ^{††}	1 (7) ^{§§}
Management of Allergic Reaction (n, %)			
Antihistamines	54 (68)	47 (72)	7 (47)
Corticosteroids	12 (15)	11 (17)	1 (7)
Epinephrine IM	6 (8)	6 (9)	0 (0)
Emergency Room Visit	19 (24)	18 (28)	1 (7)
Allergic Reaction to (n, %)			
Dose 1 (Moderna)	62 (78)	48 (74)	14 (93)
Dose 1 (Pfizer)	18 (23)	17 (26)	1 (7)
Ring and Messmer Criteria¹⁷ (n, %)			
Grade 0	22 (28)	21 (32)	1 (7)
Grade 1	46 (58)	33 (51)	13 (87)
Grade 2	12 (15)	11 (17)	1 (7)
Positive Skin Test Results (n, %)			
Miralax 1:100 (SPT)	1 (1)	1 (2)	0 (0)

Miralax 1:10 (SPT)	0 (0)	0 (0)	0 (0)
Miralax 1:1 (SPT)	0 (0)	0 (0)	0 (0)
Depo-Medrol 0.4mg/mL (IDT)	3 (4)	2 (3)	1 (7)
Depo-Medrol 4mg/mL (IDT)	1 (1)	1 (2)	0 (0)
Refresh Eye Drops 1:1 (SPT)	0 (0)	0 (0)	0 (0)
Refresh Eye Drops 1:100 (IDT)	10 (13)	5 (8)	5 (33)
Refresh Eye Drops 1:10 (IDT)	2 (3)	1 (2)	1 (7)

* Immediate was defined as 4 or fewer hours. 47 (72%) were within 1 hour, with a median of 10 minutes (IQR: 5,15)

† Delayed was defined as more than 4 hours. 11 (73%) were within 24 hours

‡ Medication 9 (14), Food 6 (9), Venom 2 (3)

§ Medication 3 (20), Food 2 (13)

¶ Hives, rash, itching, swelling (not throat), flushing

¶ Wheezing, chest tightness, shortness of breath, cough

Tachycardia, hypotension

** Gastrointestinal upset, diarrhea, vomiting, nausea

†† Throat swelling, hoarseness, globus

‡‡ Tingling (n=14, 22%), lightheaded (n=4, 6%), chest pain (n=1, 2%), feeling hot (n=1, 2%), and syncope (n=1, 2%), red eye (n=1, 2%). Patients may have more than one symptom.

§§ Sneezing (n=1, 7%), tingling (n=1, 7%). Patients may have more than one symptom.

Abbreviations: Coronavirus Disease-2019, COVID-19 Standard Deviation, SD; Polyethylene Glycol, PEG; Interquartile range, IQR; Skin prick test, SPT; intradermal test, IDT; Intramuscular, IM

Table 2. Patients with positive skin testing results. Clinical characteristics, details of first dose reaction, skin testing result, and details of second dose for patients with positive skin testing results.

	Age	Sex	Past History		Dose One Reaction					Skin Test Results	Dose Two Outcome	
			Allergies or Allergic Reaction	Prior History of Anaphylaxis	Vaccine	Onset of Symptoms	Signs and Symptoms	Treatment	Treatment Setting/Disposition			Ring and Messmer Grade
Immediate (<4 hour) Reaction	46	F	Hymenoptera venom	Yes: Hymenoptera venom	Moderna	0.16 hour	Dizziness, nausea, difficulty swallowing, swelling of eyes and tongue, hives	Diphenhydramine	Home	1	Methyl-prednisolone Acetate IDT 4 mg/ml (10x14mm) Refresh IDT 1:10 (9x21mm)	Tolerated Janssen.
	40	F	None	No	Pfizer	0.16 hour	Flushing, tachycardia, tongue itching, swelling of fingers, vomiting, diarrhea	Diphenhydramine, IV fluids, epinephrine IM, methyl-prednisolone succinate, ondansetron.	Emergency Department	1	Miralax SPT 1:100 (6x25mm)	Recommended to not receive dose two.
	26	F	Ginger	No	Moderna	0.25 hour	Wheezing	No treatment needed	Home	2	Methyl-prednisolone Acetate IDT 0.4 mg/ml (16x44mm)	Tolerated Moderna
	56	F	Omalizumab, cefaclor, sulfonamide antibiotics, nuts, shellfish, latex	No	Moderna	0.3 hour	Stinging in eyes, tingling of the tongue and lips, mild itching	Cetirizine, famotidine	Home	0	Refresh IDT 1:100 (8x11mm)	Pretreated with cetirizine 10mg and prednisone 20mg. 5 minutes after receiving dose two (Moderna), patient experienced pruritus. Treated with cetirizine 20mg.
	49	F	None	No	Moderna	1 hour	Flushing, hives, itching	Fexofenadine	Home	1	Refresh IDT (5x15mm)	Tolerated Moderna.

Delayed (>4 hour) Reaction	26	F	Environmental	No	Moderna	3 hours	Wheezing, chest tightness, dry cough	Albuterol	Home	2	Methyl-prednisolone Acetate IDT 0.4 mg/ml (10x20mm) Refresh IDT 1:100 (8x18mm)	Tolerated Moderna.
	54	M	None	No	Moderna	3 hours	Itching, lip swelling	No treatment needed	Home	1	Refresh IDT 1:100 (9x21mm)	4-6 hours after receiving dose two (Moderna), patient experienced lip swelling, which self-resolved.
	42	F	Penicillin, hymenoptera venom	No	Moderna	4 hours	Hives	No treatment needed	Home	1	Refresh IDT 1:100 (6x24mm)	Tolerated Moderna
	28	F	None	No	Moderna	10-12 hours	Itching, hives	No treatment needed	Home	1	Refresh IDT 1:100 (4x12mm)	Awaiting vaccination
	29	F	Penicillin	No	Moderna	12-16 hours	Palpitations, diarrhea, delayed hives	Loperamide	Home	0	Refresh IDT 1:100 (7x18mm)	Tolerated Moderna.
	33	F	None	No	Moderna	12-24 hours	Diffuse hives	Diphenhydramine	Home	1	Refresh IDT 1:100 (10x40mm)	Tolerated Moderna.
	24	F	Environmental	No	Moderna	18-24 hours	Wheezing, chest tightness, hives, itching	Diphenhydramine, topical hydrocortisone	Home	1	Methyl-prednisolone Acetate IDT 0.4 mg/ml (9x22mm) Refresh IDT 1:100 (13x32mm)	Tolerated Moderna.
	49	F	None	No	Pfizer	20 hours	Tongue swelling, sneezing, nasal congestion, itchy eyes, chest	Diphenhydramine, Acetaminophen, Pseudoephedrine	Home	1	Refresh IDT 1:100 (12x20mm)	Patient preference to not receive dose 2.

							congestion, cough, swelling of fingers					
19	F	Peanut, tree nuts	Yes: peanut, tree nut	Moderna	48 hours	Hives, "throat closing"	Diphenhydramine	Home	1	Refresh IDT 1:10 (11x17mm)	Pretreated with cetirizine 10mg and prednisone 20mg. 20 minutes after receiving dose two (Moderna), patient experienced dizziness, numbness in legs and fingers, warm feeling in throat. Treated with cetirizine 10mg.	

Table 3. Patients with negative skin testing results but reported a reaction to dose two. Clinical characteristics, details of first dose reaction and details of second dose reaction for patients with negative skin testing results who developed a reaction to dose two.

*Ring and Messmer Grade.¹³

	Age	Sex	Allergies or Allergic Reaction	Vaccine	Dose One Reaction				Dose Two Reaction			
					Onset of Symptoms	Signs and Symptoms	Treatment and Treatment Setting	Grade*	Onset of Symptoms	Signs and Symptoms	Treatment and Treatment Setting	Grade*
Immediate (<4 hours) Reaction	29	F	Cefuroxime, sulfonamide antibiotics, clindamycin, iodinated contrast media, ketoconazole, moxifloxacin, nystatin	Moderna	0 hours	Dizziness, fatigue, hives	Levocetirizine and diphenhydramine at home	1	0.2 hours	Hives	Diphenhydramine at the vaccine clinic and cetirizine, famotidine, and prednisone at home	1
	62	F	Sulfonamide antibiotics, latex, loratadine, morphine	Moderna	0.1 hours	Lip tingling, dizziness, eye and facial swelling	No treatment was sought	1	0.5 hours	Itching of ear, eye swelling	Diphenhydramine at the vaccine clinic and prednisone at home	1
	56	M	No known allergies	Pfizer	0.1 hours	Tongue tingling, lower lip swelling, mild throat clearing	Epinephrine, diphenhydramine, solumedrol at the emergency department	1	0.1 hours	Lower lip swelling	Cetirizine at home	1
	47	F	Latex, tramadol, amoxicillin, sulfamethoxazole-trimethoprim, fluconazole	Moderna	0.1 hours	Itching, lip tingling, subjective lip and tongue swelling, hive-like rash	Diphenhydramine at the vaccine clinic and loratadine and cetirizine at home	1	12 hours	Eye swelling and itching	Loteprednol and cetirizine at home	1
	56	F	Shrimp,	Moderna	0.1 hours	Generalized	Diphenhydramine at	0	0.2 hours	Itching,	Diphenhydramine at	0

		nitofuran- toin, ibuprofen, sulfamex- thoxazole- trimetho- prim			itching, throat itchiness, fatigue	the emergency department and albuterol at home			headache, throat tightness and itching, warmth, flushing	the emergency department	
57	F	No known allergies	Moderna	0.1 hours	Headache, throat tightness, fatigue, hypertension , redness on legs, joint and muscle aches, shakes	Ibuprofen and unspecified antihistamine at home	0	12-24 hours	Itching, rash, diarrhea, vomiting, headache, fatigue, fever, cough, muscle aches, and joint pain	Acetaminophen and diphenhydramine at home	1
46	F	Pepper, procaine	Moderna	0.2 hours	Tingling of left arm, roof of mouth, and tongue, numbness.	Cetirizine at the emergency department	0	0 hours	Numbness, chest tightness, dry heaving, chills, hot sensation in lips	Diphenhydramine, ondansetron, and methylprednisolone at the emergency department	0
24	F	Amoxi- cillin, clinda- mycin, pineapple, benzo- natate	Moderna	0.25 hours	Globus and throat itching, cough, erythemat- ous oropharynx, hoarse voice	Epinephrine, methylprednisolone sodium succinate, and diphenhydramine at the emergency department	2	0.6 hours	Throat tightness and itching, cough, erythematou s posterior pharynx, watery eyes	Cetirizine, albuterol, and epinephrine at the vaccine clinic and methylprednisolone sodium succinate, diphenhydramine, and famotidine at the emergency department	2
29	F	MMR vaccine, penicillin	Pfizer	0.3 hours	Hives, cough, hoarseness	Epinephrine, prednisone, and cetirizine at the emergency department	2	0.3 hours	Itching, rash, hives, throat tightness, cough	Epinephrine, cetirizine, and albuterol at the emergency department	2
58	F	Ciproflox-	Moderna	0.5 hours	Lip tingling,	No treatment was	1	12 hours	Lip tingling,	Unspecified	1

			acin, cephalex- in, macrolide antibiotics, NSAIDs, omepra- zole, penicillin, theophyll- ine, codeine			eye, lip, facial, and leg swelling, throat tightness	sought			lip swelling, sensation of facial swelling	antihistamine at home	
	59	F	Succinyl- choline, midazolam, prometha- zine, gabapentin, fentanyl, prochlor- perazine, cefazolin	Pfizer	1.25 hours	Sensation of throat closing, dysphagia, shortness of breath, itching of palms, soles, and torso	Diphenhydramine at the vaccine clinic	0	0.3 hours	Face, neck, and chest flushing, itching over palms and feet, lip fullness and tingling	Diphenhydramine at the vaccine clinic	1
	43	F	Ibuprofen, penicillin	Pfizer	2 hours	Lip swelling, full body itching, facial swelling, headache	Acetaminophen at home	1	0.75 hours	Tongue numbness, hive-like rash, wheezing	No treatment was sought	2
	43	F	No known allergies	Moderna	2-3 hours	Itchy rash on right arm, red and itchy right eye	No treatment was sought	1	0.1 hours	Chest flushing	No treatment was sought	1
ho ur	37	F	Cephal- osporins,	Moderna	8.5 hours	Hives, eye and lip	Diphenhydramine and loratadine at	1	0.25 hours	Arm and neck itching,	Cetirizine in the vaccine clinic	0

			penicillin, shellfish, latex, bee sting, influenza vaccine			swelling	home			arm erythema		
62	F	Iodine, shellfish	Moderna	10 hours	Hives, nausea, diarrhea	Unspecified anti- itch cream at home	1	Unknown	Throat, tongue, and eye swelling, itching of chest and face, nausea, headache, lethargy	No treatment was sought	1	

Figure E1: Skin testing protocol for PEG using Miralax for epicutaneous testing without PEG intradermal testing and PEG and polysorbate 80.

Journal Pre-proof

Table E1: Skin testing protocols used in the manuscript to test for PEG and polysorbate 80 allergy.¹³ Refresh Tears, which contains polysorbate 80 0.5%, was subsequently found to be irritating. Triamcinolone acetonide contains polysorbate 80 0.04%. *Some brands of methylprednisolone acetate contain polysorbate and PEG3350 while others only have PEG3350; use

Drug	SPT (mg/mL)	ID (mg/mL)
PEG-3350		
Miralax	1.7 17 170	
Methyl-prednisolone acetate *	40	0.4 4
Control		
Methyl-prednisolone sodium succinate	40	0.4 4
Polysorbate 80		
Triamcinolone acetonide	40	0.4 4 40
Refresh Tears	1:1	1:10

methylprednisolone acetate containing PEG3350 only.

Table E2: Ring and Messmer Grading for allergic reactions.²¹

Grade 1: Cutaneous Signs
Urticaria
Angioedema
Generalized Erythema
Grade 2: Measurable but not life-threatening symptoms
Cutaneous signs
Hypotension (defined as a decrease of more than 30% in blood pressure with tachycardia)

Cough
Difficulty with mechanical ventilation
Grade 3: Life-threatening symptoms
Cardiovascular collapse
Tachycardia or bradycardia (due to not include mild sinus tachycardia)
Arrhythmias
Severe bronchospasm
Grade 4: Death
Cardiac arrest
Respiratory arrest

Table E3: Refresh Tears skin testing results on non-allergic, clinically tolerant controls, reflecting a high frequency of false positive, irritant reactions. Among 25 non-allergic controls, there were 13 (52%) positive reactions to Refresh Tears on intradermal testing, with 8 (32%) positive at the 1:100 concentration and 5 (20%) positive at the 1:10 concentration

Patient	Refresh Tears 1:100 (ID) (mm, wheal x flare)	Refresh Tears 1:10 (ID) (mm, wheal x flare)
1	10 x 20	--
2	0	7 x 15
3	0	8 x 18
4	0	0
5	8 x 18	--
6	9 x 14	--
7	0	0
8	0	0
9	0	0
10	0	0
11	8 x 13	--
12	0	0
13	9 x 20	--
14	0	7 x 18
15	0	0
16	0	--
17	0	--

18	0	6 x 24
19	0	0
20	0	0
21	0	0
22	8 x 18	--
23	7 x 8	--
24	0	4 x 8
25	5 x 10	--
Total:	8 (32%)	5 (20%)